| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_280d87031f0c5786de1808713a1b76b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59c6a921f33fe0adc58c2b6177184515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3127c0ebee3f865b211b019fac84286 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0497 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-083
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 |
| filingDate |
2018-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_045ae7c392efbc8c7bb493f2995fbb0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_317a7409dfc6499f9c73c17e7fb37b82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1180292a7dca5c0ee01d0e6488d7a1d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d42a8662c1cf661814e6f33063330243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c166cdebd1c3da72f4de3a358489e6fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e8598f901d62888fcd036616fab8f2a |
| publicationDate |
2019-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019263857-A1 |
| titleOfInvention |
Toll-like receptor 2 ligands and methods of making and using thereof |
| abstract |
Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only −½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation. |
| priorityDate |
2015-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |